ideasIdea
Blunt the inflammation that wakes sleeping cancer cells
Inflammation from infection, injury or surgery can wake dormant cancer cells. Blocking one key inflammatory signal might keep them asleep.
Interleukin-1 beta from the bone marrow niche drives the exit of breast cancer cells from dormancy and metastatic outgrowth in mouse models, and a large cardiovascular trial of canakinumab reported an unexpected reduction in lung cancer incidence and mortality. Later lung cancer treatment trials of canakinumab in advanced disease were negative, which is consistent with awakening being an early, not late, event.
Hypothesis
Interleukin-1 beta blockade in high-risk survivors reduces distant relapse rate, whereas the same drug has no effect in established metastatic disease.
Rationale
Setting-dependence is the crux: an awakening inhibitor cannot shrink a tumour that is already growing. Testing prevention rather than treatment aligns the mechanism with the endpoint, and the CANTOS incidence signal is a human-level hint that the axis matters.
What would test it
A randomised trial in ctDNA-positive or clinically high-risk resected breast or lung cancer with relapse-free survival and ctDNA clearance as co-primary endpoints, powered for a modest effect and sized off the CANTOS incidence data.
Maturity
preclinical evidence
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
7
Bottlenecks it attacks
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.